COVID-19 Vaccine Covishield Gets Approval From DCGI’s Expert
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Covishield, the vaccine candidate from Pune-based Serum Institute of India, was approved by a Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) late on Friday.The nod for Covishield came at the end of a marathon meeting of the SEC. They gave its recommendation to the DCGI.

Covishield is likely to be practically available for use within the next week, the source said. “Similar to that in the United Kingdom, we've approved the vaccine to be given in two doses 4-12 weeks apart.”

SII officials have said India will have a stockpile of 100 million doses as of the first week of January but there is no clarity on how many of these will be available for Indians. A longer dosage interval means that potentially more Indians could get at least a single jab of the vaccine.

Covishield is currently being tested in 1,600 volunteers as part of its phase 2/3 trial. The phase 3 trial is ongoing and the data is continuously being reviewed. Other than the case from Chennai of a reported severe adverse event from the vaccine, no other safety events have been reported.

Source:
1.https://www.thehindu.com/news/national/coronavirus-serum-institute-of-indias-covid-19-vaccine-covishield-likely-to-be-approved-for-emergency-use-in-india/article33472324.ece
2.https://twitter.com/ANI/status/1345319176454303745
Dr. T●●●●z H●●●●●●i and 8 others like this3 shares
Like
Comment
Share